Company family · HQ BE
UCB: medicine shortages
As of 2 Nov 2026, 6 UCB products have a reported shortage across 3 countries, covering 2 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changes| Date | Country | Medicine | Change |
|---|---|---|---|
| 2 Nov | BE | Certolizumab Pegol Cimzia 200 mg (Orifarm) inj. sol. s.c. pre-filled syr. 2 x 1 ml | return pushed back 31 Oct → 31 Dec |
Open shortages over time
Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Certolizumab Pegol | 3 | 3 Dec 2024 | Other | 2/16 | |
| Sodium Oxybate | 3 | 1 Jul 2026 | Not stated | 2/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.